Kamil R Kranc
Overview
Explore the profile of Kamil R Kranc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lawson H, Holt-Martyn J, Dembitz V, Kabayama Y, Wang L, Bellani A, et al.
Nat Cancer
. 2024 Apr;
5(6):916-937.
PMID: 38637657
Acute myeloid leukemia (AML) is a largely incurable disease, for which new treatments are urgently needed. While leukemogenesis occurs in the hypoxic bone marrow, the therapeutic tractability of the hypoxia-inducible...
2.
3.
Dembitz V, Durko J, Campos J, James S, Lawson H, Kranc K, et al.
Hemasphere
. 2024 Mar;
8(1):e28.
PMID: 38434525
No abstract available.
4.
Kucinski I, Campos J, Barile M, Severi F, Bohin N, Moreira P, et al.
Cell Stem Cell
. 2024 Jan;
31(2):244-259.e10.
PMID: 38183977
The paradigmatic hematopoietic tree model is increasingly recognized to be limited, as it is based on heterogeneous populations largely defined by non-homeostatic assays testing cell fate potentials. Here, we combine...
5.
Gorur V, Kranc K, Ganuza M, Telfer P
Blood Rev
. 2023 Nov;
63:101137.
PMID: 37919142
Gene modification of haematopoietic stem cells (HSCs) is a potentially curative approach to sickle cell disease (SCD) and offers hope for patients who are not eligible for allogeneic HSC transplantation....
6.
Woodley K, Dillingh L, Giotopoulos G, Madrigal P, Rattigan K, Philippe C, et al.
Nat Commun
. 2023 Apr;
14(1):2132.
PMID: 37059720
Resistance to standard and novel therapies remains the main obstacle to cure in acute myeloid leukaemia (AML) and is often driven by metabolic adaptations which are therapeutically actionable. Here we...
7.
Edwards-Hicks J, Su H, Mangolini M, Yoneten K, Wills J, Rodriguez-Blanco G, et al.
Nat Commun
. 2022 Aug;
13(1):4674.
PMID: 35945217
The MYC oncogene is a potent driver of growth and proliferation but also sensitises cells to apoptosis, which limits its oncogenic potential. MYC induces several biosynthetic programmes and primary cells...
8.
Young C, Russell J, van de Lagemaat L, Lawson H, Mapperley C, Kranc K, et al.
Biol Open
. 2022 May;
11(6).
PMID: 35603697
Peptidylarginine deiminases (PADIs) are strongly associated with the development of autoimmunity, neurodegeneration and cancer but their physiological roles are ill-defined. The nuclear deiminase PADI4 regulates pluripotency in the mammalian pre-implantation...
9.
Sommerkamp P, Brown J, Haltalli M, Mercier F, Vu L, Kranc K
Exp Hematol
. 2022 Apr;
111:25-31.
PMID: 35487293
Post-transcriptional RNA modifications determine RNA fate by influencing numerous processes such as translation, decay and localization. One of the most abundant RNA modifications is N-methyladenoside (mA), which has been shown...
10.
Turner D, Saveliev A, Salerno F, Matheson L, Screen M, Lawson H, et al.
Elife
. 2022 Apr;
11.
PMID: 35451955
To identify roles of RNA binding proteins (RBPs) in the differentiation or survival of antibody secreting plasma cells we performed a CRISPR/Cas9 knockout screen of 1213 mouse RBPs for their...